As over half of Americans now receive prescriptions through Medicare or Medicaid, pharma companies must shift from a commercial-first approach to a statutory-first model, making GTN governance a ...

This episode of Pharma Pulse discusses a new executive order to build a domestic API stockpile, Eli Lilly’s 170% price ...

In the second part of his Pharma Commerce video interview, Dave Malenfant, a healthcare supply chain expert, outlines how the impact of a steep pharmaceutical import tariff varies across raw materials ...

Two Labs’ Michael Rowe assesses the industry’s level of preparation, including challenges stakeholders have encountered along ...

The directive calls for building a six-month Strategic Active Pharmaceutical Ingredients Reserve, updating the essential ...

The US drug wholesaling industry is stable post-opioid settlement, with focus shifting to fund management and pharmacy ...

This episode of Pharma Pulse explores AbbVie’s $195 million investment to expand US API production, new survey results ...

In the first part of his Pharma Commerce video interview, Mark Lee, MarqVision’s founder and CEO, warns that counterfeiters ...

As pharma drug pricing debates heat up, the 340B program faces mounting challenges from outdated regulations, duplicate ...

The new North Chicago facility, slated to open in 2027, will boost domestic production of key drug ingredients for immunology ...

Pharma must align data, personalization, and cross-functional orchestration to deliver human-centered experiences that ...

This episode of Pharma Pulse dives into Cardinal Health’s acquisition of Solaris Health to strengthen specialty services, how ...